PT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 1/by MaxEmerging Radiopharmaceuticals for Low PSMA-Expressing Prostate Cancer: 67Cu-SAR-bisFAP and 67Cu-SAR-bombesin
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial: AVA6000 Targeted Chemotherapy for FAP-Positive Tumors (Including Prostate Cancer)
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial of QXL138AM: A Targeted Therapy for Prostate Cancer and Other CD138-Expressing Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial of INV-9956: A Promising CYP11A1 Inhibitor Targeting Drug-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Enrolling: Novel Copper-61 Radiotracer Shows Promise in Prostate Cancer Precision Imaging
/in Clinical Trial, Localized, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026